US EditionPublished • loading... • Updated
Early Cancer Signal Emerges as Aprea Drug Shrinks Tumors in Phase 1 Trial
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Early Cancer Signal Emerges as Aprea Drug Shrinks Tumors in Phase 1 Trial
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported its first unconfirmed partial response in a Phase 1 study of its experimental cancer drug APR-1051, an early signal the company says provides proof-of-concept for single-agent activity in patients with advanced solid tumors. The response was observed in a patient with PPP2R1A-mutated uterine serous carcinoma, a rare and aggressive form of endometrial cancer, enrolled in Aprea’s on…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
